Early biochemical relapse after radical prostatectomy: Which prostate cancer patients may benefit from a restaging 11C-choline PET/CT scan before salvage radiation therapy?

Journal of Nuclear Medicine

Volumn 55, Issue 9, 2014, Pages 1424-1429

  Castellucci, Paolo ^a   Ceci, Francesco ^a   Graziani, Tiziano ^a   Schiavina, Riccardo ^a   Brunocilla, Eugenio ^a   Mazzarotto, Renzo ^a   Pettinato, Cinzia ^a   Celli, Monica ^a   Lodi, Filippo ^a   Fanti, Stefano ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

11C choline PET CT; Biochemical relapse; Prostate cancer; PSA kinetics; Risk factors

Indexed keywords

CHOLINE C 11; PROSTATE SPECIFIC ANTIGEN; CARBON; CHOLINE; DIAGNOSTIC AGENT;

AGED; ANDROGEN DEPRIVATION THERAPY; AREA UNDER THE CURVE; ARTICLE; BONE SCINTISCANNING; BRACHYTHERAPY; CANCER DIAGNOSIS; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CHEMICAL ANALYSIS; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTRAST ENHANCEMENT; CONTROLLED STUDY; DIGITAL RECTAL EXAMINATION; DISTANT METASTASIS; EXTERNAL BEAM RADIOTHERAPY; GLEASON SCORE; HUMAN; IMAGE ANALYSIS; MAJOR CLINICAL STUDY; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PELVIS LYMPH NODE; PROBABILITY; PROSTATE CANCER; PROSTATECTOMY; RECEIVER OPERATING CHARACTERISTIC; RETROSPECTIVE STUDY; RISK FACTOR; SALVAGE THERAPY; SENSITIVITY AND SPECIFICITY; TRANSRECTAL ULTRASONOGRAPHY; TUMOR GROWTH; 11C-CHOLINE PET/CT; BIOCHEMICAL RELAPSE; BLOOD; COMPUTER ASSISTED TOMOGRAPHY; MIDDLE AGED; MULTIMODAL IMAGING; POSITRON EMISSION TOMOGRAPHY; PROSTATE TUMOR; PSA KINETICS; SCINTISCANNING; TUMOR RECURRENCE; VERY ELDERLY;

11C-CHOLINE PET/CT; BIOCHEMICAL RELAPSE; PROSTATE CANCER; PSA KINETICS; RISK FACTORS;

AGED; AGED, 80 AND OVER; CARBON RADIOISOTOPES; CHOLINE; HUMANS; MALE; MIDDLE AGED; MULTIMODAL IMAGING; NEOPLASM RECURRENCE, LOCAL; POSITRON-EMISSION TOMOGRAPHY; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES; SALVAGE THERAPY; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84907015036     PISSN: 01615505     EISSN: 2159662X     Source Type: Journal    
DOI: 10.2967/jnumed.114.138313     Document Type: Article

References (30)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69-90.
2. Heidenreich A, Bellmunt J, Bolla M, et al. EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localised disease. Eur Urol. 2011;59:61-71.
3. Mottet N, Bellmunt J, Bolla M, et al. EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur Urol. 2011;59:572-583.
4. Freedland SJ, Presti JC Jr, Amling CL, et al. Time trends in biochemical recurrence after radical prostatectomy: results of the SEARCH database. Urology. 2003;61:736-741.
5. Kane CJ, Amling CL, Johnstone PAS, et al. Limited value of bone scintigraphy and computed tomography in assessing biochemical failure after radical prostatectomy. Urology. 2003;61:607-611.
6. Choueiri TK, Dreicer R, Paciorek A, Carroll PR, Konety B. A model that predicts the probability of positive imaging in prostate cancer cases with biochemical failure after initial definitive local therapy. J Urol. 2008;179:906-910.
7. Martino P, Scattoni V, Galosi AB, et al. Role of imaging and biopsy to assess local recurrence after definitive treatment for prostate carcinoma (surgery, radiotherapy, cryotherapy, HIFU). World J Urol. 2011;29:595-605.
8. Cirillo S, Petracchini M, Scotti L, et al. Endorectal magnetic resonance imaging at 1.5 Tesla to assess local recurrence following radical prostatectomy using T2- weighted and contrast-enhanced imaging. Eur Radiol. 2009;19:761-769.
9. Pfister D, Bolla M, Briganti A, et al. Early salvage radiotherapy following radical prostatectomy. Eur Urol. 2014;65:1034-1043.
10. Stephenson AJ, Scardino PT, Kattan MW, et al. Predicting the outcome of salvage radiation therapy for recurrent prostate cancer after radical prostatectomy. J Clin Oncol. 2007;25:2035-2041.
11. Stephenson AJ, Bolla M, Briganti A, et al. Postoperative radiation therapy for pathologically advanced prostate cancer after radical prostatectomy. Eur Urol. 2012;61:443-451.
12. Rigatti P, Suardi N, Briganti A, et al. Pelvic/retroperitoneal salvage lymph node dissection for patients treated with radical prostatectomy with biochemical recurrence and nodal recurrence detected by [11C]choline positron emission tomography/ computed tomography. Eur Urol. 2011;60:935-943.
13. Würschmidt F, Petersen C, Wahl A, Dahle J, Kretschmer M. [18F]fluoroethylcholine- PET/CT imaging for radiation treatment planning of recurrent and primary prostate cancer with dose escalation to PET/CT-positive lymph nodes. Radiat Oncol. 2011;1;6:44.
14. Berkovic P, De Meerleer G, Delrue L, et al. Salvage stereotactic body radiotherapy for patients with limited prostate cancer metastases: deferring androgen deprivation therapy. Clin Genitourin Cancer. 2013;11:27-32.
15. Fuccio C, Rubello D, Castellucci P, Marzola MC, Fanti S. Choline PET/CT for prostate cancer: main clinical applications. Eur J Radiol. 2011;80:e50-e56.
16. Castellucci P, Fuccio C, Nanni C, et al. Influence of trigger PSA and PSA kinetics on11C-choline PET/CT detection rate in patients with biochemical relapse after radical prostatectomy. J Nucl Med. 2009;50:1394-1400.
17. Krause BJ, Souvatzoglou M, Tuncel M, et al. The detection rate of [11C]choline- PET/CT depends on the serum PSA-value in patients with biochemical recurrence of prostate cancer. Eur J Nucl Med Mol Imaging. 2008;35:18-23.
18. Castellucci P, Fuccio C, Rubello D, et al. Is there a role for11C-choline PET/CT in the early detection of metastatic disease in surgically treated prostate cancer patients with a mild PSA increase ,1.5 ng/ml? Eur J Nucl Med Mol Imaging. 2011;38:55-63.
19. Mamede M, Ceci F, Castellucci P, et al. The role of11C-choline PET imaging in the early detection of recurrence in surgically treated prostate cancer with very low PSA level < 0.5 ng/mL. Clin Nucl Med. 2013;38:e342-e345.
20. Pascali C, Bogni A, Iwata R.11C-methylation on 18C SepPak cartridge: a convenient way to produce [N-methyl-11C] choline. J Labelled Comp Radiopharm. 2000;49:195-203.
21. Ceci F, Castellucci P, Mamede M, et al.11C-choline PET/CT in patients with hormone-resistant prostate cancer showing biochemical relapse after radical prostatectomy. Eur J Nucl Med Mol Imaging. 2013;40:149-155.
22. Ceci F, Castellucci P, Graziani T, et al.11C-choline PET/CT detects the site of relapse in the majority of prostate cancer patients showing biochemical relapse after EBRT. Eur J Nucl Med Mol Imaging. 2014;41:878-886.
23. Khan MA, Carter HB, Epstein JI, et al. Can prostate specific antigen derivatives and pathological parameters predict significant change in expectant management criteria for prostate cancer? J Urol. 2003;170:2274-2278.
24. Mohler J, Bahnson RR, Boston B, et al. NCCN clinical practice guidelines in oncology: prostate cancer. J Natl Compr Canc Netw. 2010;8:162-200.
25. Katz MS, Zelefsky MJ, Venkatraman ES, et al. Predictors of biochemical outcome with salvage conformal radiotherapy after radical prostatectomy for prostate cancer. J Clin Oncol. 2003;21:483-489.
26. Leventis AK, Shariat SF, Kattan MW, et al. Prediction of response to salvage radiation therapy in patients with prostate cancer recurrence after radical prostatectomy. J Clin Oncol. 2001;19:1030-1039.
27. Mir MC, Li J, Klink JC, Kattan MW, Klein EA. Stephenson AJ. Optimal definition of biochemical recurrence after radical prostatectomy depends on pathologic risk factors: identifying candidates for early salvage therapy. Eur Urol. August 20, 2013 [Epub ahead of print].
28. Fuccio C, Castellucci P, Schiavina R, et al. Role of11C-choline PET/CT in the restaging of prostate cancer patients with biochemical relapse and negative results at bone scintigraphy. Eur J Radiol. 2012;81:e893-e896.
29. Souvatzoglou M, Krause BJ, Pürschel A, et al. Influence of11C-choline PET/CT on the treatment planning for salvage radiation therapy in patients with biochemical recurrence of prostate cancer. Radiother Oncol. 2011;99:193-200.
30. Giovacchini G, Picchio M, Garcia-Parra R, et al.11C-choline PET/CT predicts prostate cancer-specific survival in patients with biochemical failure during androgen-deprivation therapy. J Nucl Med. 2014;55:233-241.